Simulation of High Conversion Efficiency and Open-circuit Voltages Of {\alpha}-si/poly-silicon Solar Cell

The P+ {\alpha}-Si /N+ polycrystalline solar cell is molded using the AMPS-1D device simulator to explore the new high efficiency thin film poly-silicon solar cell. In order to analyze the characteristics of this device and the thickness of N+ poly-silicon, we consider the impurity concentration in the N+ poly-silicon layer and the work function of transparent conductive oxide (TCO) in front contact in the calculation. The thickness of N+ poly-silicon has little impact on the device when the thickness varies from 20 {\mu}m to 300 {\mu}m. The effects of impurity concentration in polycrystalline are analyzed. The conclusion is drawn that the open-circuit voltage (Voc) of P+ {\alpha}-Si /N+ polycrystalline solar cell is very high, reaching 752 mV, and the conversion efficiency reaches 9.44%. Therefore, based on the above optimum parameters the study on the device formed by P+ {\alpha}-Si/N+ poly-silicon is significant in exploring the high efficiency poly-silicon solar cell.Comment: 8 pages 6figures, 1 table

Photoelectric effect on an Al/SiO2/p-Si Schottky diode structure

A SiO _2 of 200 nm thickness layer was grown via thermal oxidation to obtain an Al/SiO _2 /p-Si MIS Schottky diode structure with top contacts and different active areas. Electrical measurements of MIS Schottky diode structure allow to observe the photoelectric effect only in the device with higher active area, as well as to obtain some electrical parameters such as the barrier height, the ideality factor and the density of interface states, which correspond to 0.97 eV, 1.46 and 4.44 × 10 ^10 eV ^−1 cm ^−2 respectively. Furthermore, a fill factor of 0.202 and power conversion efficiency less than 1%. On the other hand, Capacitance-Voltage (C–V) measurements depict a positive and negative capacitance peaks at low frequencies; this behavior and photoelectric effect are attributed to the density of interface states at SiO _2 /p-Si, as well as to the Space-Charge-Limited Conduction process in the insulation layer. Furthermore, the use of this kind of insulator can allows increasing the conversion efficiency if it is used as bottom n-layer or front contact in tandem solar cells and silicon heterojunction solar cells, respectively

Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity trial results

BACKGROUND: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19). METHODS: We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. RESULTS: At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan–Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P=0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P=0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. CONCLUSIONS: These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.</p